These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 29898992)

  • 1. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
    Marciscano AE; Ghasemzadeh A; Nirschl TR; Theodros D; Kochel CM; Francica BJ; Muroyama Y; Anders RA; Sharabi AB; Velarde E; Mao W; Chaudhary KR; Chaimowitz MG; Wong J; Selby MJ; Thudium KB; Korman AJ; Ulmert D; Thorek DLJ; DeWeese TL; Drake CG
    Clin Cancer Res; 2018 Oct; 24(20):5058-5071. PubMed ID: 29898992
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 3. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.
    Dovedi SJ; Cheadle EJ; Popple AL; Poon E; Morrow M; Stewart R; Yusko EC; Sanders CM; Vignali M; Emerson RO; Robins HS; Wilkinson RW; Honeychurch J; Illidge TM
    Clin Cancer Res; 2017 Sep; 23(18):5514-5526. PubMed ID: 28533222
    [No Abstract]   [Full Text] [Related]  

  • 4. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
    Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
    Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
    Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
    [No Abstract]   [Full Text] [Related]  

  • 6. Intratumoral CD8
    Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
    Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation.
    Jing H; Hettich M; Gaedicke S; Firat E; Bartholomä M; Niedermann G
    J Immunother Cancer; 2019 Feb; 7(1):55. PubMed ID: 30808414
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    De La Maza L; Wu M; Wu L; Yun H; Zhao Y; Cattral M; McCart A; Cho BJ; de Perrot M
    Clin Cancer Res; 2017 Sep; 23(18):5502-5513. PubMed ID: 28606922
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
    Hosoi A; Takeda K; Nagaoka K; Iino T; Matsushita H; Ueha S; Aoki S; Matsushima K; Kubo M; Morikawa T; Kitaura K; Suzuki R; Kakimi K
    Sci Rep; 2018 Jan; 8(1):1058. PubMed ID: 29348598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.
    Hu J; Sun C; Bernatchez C; Xia X; Hwu P; Dotti G; Li S
    Clin Cancer Res; 2018 Jun; 24(12):2920-2934. PubMed ID: 29391351
    [No Abstract]   [Full Text] [Related]  

  • 12. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 13. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
    Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
    Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
    Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
    Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.
    van Pul KM; Fransen MF; van de Ven R; de Gruijl TD
    Front Immunol; 2021; 12():643291. PubMed ID: 33732264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
    Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
    Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy.
    Boss MK; Watts R; Harrison LG; Hopkins S; Chow L; Trageser E; Easton C; LaRue SM; Regan D; Dewhirst MW; Dow S
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.